Results 191 to 200 of about 783,628 (249)

A novel assay for quantifying Gn-LRP1-mediated neutralizing antibodies against severe fever with thrombocytopenia syndrome virus. [PDF]

Emerg Microbes Infect
Hu LF, Tu MY, Zhang DY, Sun MR, Liu SY, Li YY, Liu MY, Wang Y, Lim BL, Li JB, Tan CW, Wang LF.   +11 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Lipid Nanoparticle Protein Coronas Arise through Lipoprotein Fusion Rather Than Shell-like Adsorption. [PDF]

Nano Lett
Grumelot S, Mohammed N, Yerima G, Colonrosado J, Sadeghi SA, Fang F, Hilsen K, Shango B, Saei AA, Murray AM, Mitchell MJ, Borhan B, Sun L, Vali H, Mofrad MRK, Whitehead KA, Mahmoudi M.   +16 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells. [PDF]

J Clin Invest
Cabodevilla AG, Calistru C, Younis W, Nasias D, Ho TW, Anaganti N, Valmiki S, Rajan S, Gjini J, Kore R, Hannemann C, Davidson NO, Vaisar T, Kanter JE, Bornfeldt KE, Fisher EA, Lee WL, Madl T, Hussain MM, Goldberg IJ.   +19 more
europepmc   +1 more source

Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio, Takashi Nagasaka, Ryota Taniuchi, Shiro Amanai, Yohei Ishibashi, Noriaki Takama, Hideki Ishii   +6 more
wiley   +1 more source

LR11/SorLA and its role in cardiovascular disease. [PDF]

Int J Cardiol Heart Vasc
Kloosterman M, Vongpromek R, Friesema ECH, Bramer W, Verhoeven AJM, Mulder MT.   +5 more
europepmc   +1 more source

Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized.
Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Dae‐Won Kim, Kiyuk Chang   +5 more
wiley   +1 more source

Amelioration of the neurological phenotype in PKU mouse model emphasizes the potential of base editing for metabolic diseases. [PDF]

Mol Ther Adv
Keskinen T, Hyvönen ME.
europepmc   +1 more source

Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon   +6 more
wiley   +1 more source